Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief ...
Halozyme price target raised to $72 from $70 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $72 from $70 and keeps a Buy rating on the shares following the Q4 report.
DRDGold price target lowered to $16.25 from $17.25 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on DRDGold (DRD) to $16.25 from $17.25 and keeps a Buy rating on the shares following the first ...
HC Wainwright Reaffirms Buy Rating for Western Copper & Gold (NYSE:WRN)
HC Wainwright restated their buy rating on shares of Western Copper & Gold (NYSE:WRN – Free Report) in a research report released on Tuesday morning,Benzinga reports. The firm currently has a $4.25 ...
Vanda Pharmaceuticals (NASDAQ:VNDA) Given New $20.00 Price Target at HC Wainwright
Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) had its price target upped by HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Tuesday morning,Benzinga reports. HC ...